vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and STRATASYS LTD. (SSYS). Click either name above to swap in a different company.
STRATASYS LTD. is the larger business by last-quarter revenue ($137.0M vs $94.9M, roughly 1.4× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -40.6%, a 69.0% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs -2.2%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $2.5M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs -7.4%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
DVAX vs SSYS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $137.0M |
| Net Profit | $26.9M | $-55.6M |
| Gross Margin | — | 41.0% |
| Operating Margin | 22.4% | -16.6% |
| Net Margin | 28.4% | -40.6% |
| Revenue YoY | 17.7% | -2.2% |
| Net Profit YoY | 53.0% | -109.0% |
| EPS (diluted) | $0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $94.9M | $137.0M | ||
| Q2 25 | $95.4M | $138.1M | ||
| Q1 25 | $68.2M | $136.0M | ||
| Q4 24 | $72.0M | — | ||
| Q3 24 | $80.6M | $140.0M | ||
| Q2 24 | $73.8M | $138.0M | ||
| Q1 24 | $50.8M | $144.1M | ||
| Q4 23 | $55.6M | — |
| Q3 25 | $26.9M | $-55.6M | ||
| Q2 25 | $18.7M | $-16.7M | ||
| Q1 25 | $-96.1M | $-13.1M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $17.6M | $-26.6M | ||
| Q2 24 | $11.4M | $-25.7M | ||
| Q1 24 | $-8.7M | $-26.0M | ||
| Q4 23 | $219.0K | — |
| Q3 25 | — | 41.0% | ||
| Q2 25 | — | 43.1% | ||
| Q1 25 | — | 44.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 44.8% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 44.4% | ||
| Q4 23 | — | — |
| Q3 25 | 22.4% | -16.6% | ||
| Q2 25 | 15.1% | -12.0% | ||
| Q1 25 | -34.7% | -9.1% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 12.5% | -18.2% | ||
| Q2 24 | 7.0% | -18.9% | ||
| Q1 24 | -35.0% | -17.0% | ||
| Q4 23 | -15.3% | — |
| Q3 25 | 28.4% | -40.6% | ||
| Q2 25 | 19.6% | -12.1% | ||
| Q1 25 | -141.0% | -9.6% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 21.8% | -19.0% | ||
| Q2 24 | 15.4% | -18.6% | ||
| Q1 24 | -17.2% | -18.0% | ||
| Q4 23 | 0.4% | — |
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.12 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.07 | — | ||
| Q4 23 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $71.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $852.5M |
| Total Assets | $946.5M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $160.2M | $71.5M | ||
| Q2 25 | $99.1M | $71.1M | ||
| Q1 25 | $51.7M | $70.1M | ||
| Q4 24 | $95.9M | — | ||
| Q3 24 | $119.3M | $64.0M | ||
| Q2 24 | $112.5M | $70.9M | ||
| Q1 24 | $132.0M | $91.1M | ||
| Q4 23 | $150.3M | — |
| Q3 25 | $534.1M | $852.5M | ||
| Q2 25 | $494.2M | $902.4M | ||
| Q1 25 | $530.9M | $784.8M | ||
| Q4 24 | $596.8M | — | ||
| Q3 24 | $681.4M | $831.8M | ||
| Q2 24 | $642.8M | $850.5M | ||
| Q1 24 | $618.5M | $866.1M | ||
| Q4 23 | $622.1M | — |
| Q3 25 | $946.5M | $1.1B | ||
| Q2 25 | $918.4M | $1.1B | ||
| Q1 25 | $945.9M | $1.0B | ||
| Q4 24 | $986.3M | — | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $986.6M | $1.1B | ||
| Q4 23 | $997.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $6.9M |
| Free Cash FlowOCF − Capex | $32.6M | $2.5M |
| FCF MarginFCF / Revenue | 34.4% | 1.8% |
| Capex IntensityCapex / Revenue | 1.3% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $-11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $33.8M | $6.9M | ||
| Q2 25 | $23.4M | $-1.1M | ||
| Q1 25 | $-19.6M | $4.5M | ||
| Q4 24 | $53.0M | — | ||
| Q3 24 | $19.5M | $-4.5M | ||
| Q2 24 | $10.7M | $-2.4M | ||
| Q1 24 | $-16.7M | $7.3M | ||
| Q4 23 | $13.8M | — |
| Q3 25 | $32.6M | $2.5M | ||
| Q2 25 | $22.0M | $-8.4M | ||
| Q1 25 | $-23.6M | $789.0K | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | $-6.3M | ||
| Q2 24 | $9.9M | $-4.9M | ||
| Q1 24 | $-17.4M | $5.0M | ||
| Q4 23 | $12.0M | — |
| Q3 25 | 34.4% | 1.8% | ||
| Q2 25 | 23.0% | -6.1% | ||
| Q1 25 | -34.6% | 0.6% | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | -4.5% | ||
| Q2 24 | 13.5% | -3.6% | ||
| Q1 24 | -34.3% | 3.5% | ||
| Q4 23 | 21.7% | — |
| Q3 25 | 1.3% | 3.2% | ||
| Q2 25 | 1.5% | 5.3% | ||
| Q1 25 | 5.8% | 2.8% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.1% | 1.8% | ||
| Q1 24 | 1.5% | 1.6% | ||
| Q4 23 | 3.1% | — |
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 62.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
SSYS
Segment breakdown not available.
